🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Alain P. Algazi

University of California, San Francisco

ORCID: 0000-0001-6576-4659

Also affiliated with UCSF Helen Diller Family Comprehensive Cancer Center

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes”.

Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes

Cell(2023)10.1016/j.cell.2023.02.021

N/A

4.9DataRank · unranked

421 citations

Trine Line Hauge Okholm, Kyle B. Jones, Elizabeth McCarthy, Candace C. Liu, Jacqueline L. Yee +18 more

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

Neuro-Oncology(2021)10.1093/neuonc/noab094

N/A

4.0DataRank · unranked

126 citations

Peter Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid +18 more

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

Cancer Cell(2021)10.1016/j.ccell.2021.07.023

N/A

3.9DataRank · unranked

135 citations

Sixue Liu, Zhentao Yang, Alain P. Algazi, Shirley H. Lomeli, Yan Wang +16 more

Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2547

N/A

1.3DataRank · unranked

29 citations

Courtney B. Betts, Lauren Maloney, Eric Nadler, Alain P. Algazi, Michael J. Guarino +10 more

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Nature Communications(2020)10.1038/s41467-020-19810-w

N/A

0.675DataRank · unranked

89 citations

Alain P. Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael S. Gordon +10 more

A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers

Cancer(2024)10.1002/cncr.35200

N/A

0.612DataRank · unranked

12 citations

James Moon, Christopher D. Lao, Bartosz Chmielowski, Kari Kendra, Karl D. Lewis +12 more

Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10059

N/A

0DataRank · unranked

0 citations

Megan Othus, Benjamin Newell Voorhies, Kari Kendra, Shaker R. Dakhil, Amy Harker-Murray +6 more

Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10039

N/A

0DataRank · unranked

1 citations

Megan Othus, Adil Daud, Janice M. Mehnert, Thach‐Giao Truong, Robert M. Conry +15 more